Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.

@article{Saag2018DenosumabVR,
  title={Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study.},
  author={Kenneth G Saag and Rachel B. Wagman and P. Geusens and Jonathan Derek Adachi and Osvaldo Daniel Messina and Ronald D Emkey and Roland D. Chapurlat and Andrea T Wang and Nicola Pannacciulli and Willem Frederik Lems},
  journal={The lancet. Diabetes & endocrinology},
  year={2018},
  volume={6 6},
  pages={445-454}
}
BACKGROUND Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and is associated with an estimated annual fracture rate of 5%. We aimed to assess the efficacy and safety of denosumab compared with risedronate in glucocorticoid-induced osteoporosis. METHODS We did a 24-month, double-blind, active-controlled, double-dummy, non-inferiority study at 79 centres in Europe, Latin America, Asia, and North America. Eligible patients were aged 18 years or older and… CONTINUE READING
5 Citations
31 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…